As Congress considers legislation that would allow imitative biological products, known as "biosimilars," to rely on the safety and efficacy data of original innovators, it must ensure that any provisions passed will foster, not stifle, discovery.

Ernst R. Berndt and Anjli C. Warner discuss their new book, U.S. Markets for Vaccines: Characteristics, Case Studies, and Controversies.

The 1984 Hatch-Waxman Act created a streamlined path for generic drugs to reach the market after pioneer drug patents expire. The result has been the most vigorous and competitive generic drug market in the world, but the Hatch-Waxman Act does not apply to most biologics. Isolated from a variety of...

The U.S. health system is recognized as the world's leader in clinical innovation, yet millions of Americans do not have health insurance, reducing their access to those life-enhancing and life-saving treatments. AEI has invited twenty academic experts from around the country as well as members of the...

Presidential and congressional candidates are now offering several new policy proposals that would affect the pharmaceutical industry. Most of these would attempt to control the price of pharmaceutical products or affect prices by increasing the supply of imported or reimported products. One of the principal policy issues raised by...

This book discusses health care reform and how pharmaceutical innovations can be developed to ensure the healthy future of America.